Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipase A2 receptor 1 (PLA2R1)
- Target
- PLA2R1
- Molecular classification
- Receptor (Type I transmembrane receptor), C-type lectin-like receptor (member CLEC13C)
01
Overview
Phospholipase A2 receptor 1 (PLA2R1) is a transmembrane receptor that binds secretory phospholipase A2 enzymes, mediating diverse signaling events in immune cells and podocytes. Its principal clinical role is as the major antigenic target for autoantibodies in idiopathic membranous nephropathy. PLA2R1 participates in cell signaling pathways (MAPK cascade), endocytosis, regulation of cell survival, tissue homeostasis, and acts as a suppressor of tumorigenesis and cellular senescence. Genetic and serological biomarkers (anti-PLA2R1 antibodies, risk alleles) are used for disease diagnosis, prognosis, and monitoring; therapeutic strategies include B-cell targeted drugs and standard immunosuppression. The receptor is also implicated in inflammation, tissue injury responses, and may regulate podocyte adhesion in the kidney glomerular basement membrane.
- Other names
- Secretory phospholipase A2 receptorPLA2RPLA2-RCLEC13CPLA2G1RPLA2IR180 kDa secretory phospholipase A2 receptorC-type lectin domain family 13 member CM-type receptor
02
Mechanism of action
B-cell depletion (rituximab removes antibody-producing cells, reducing pathogenic anti-PLA2R1 antibodies) Immunosuppression (other drugs suppress immune response, lowering autoantibody titers)
03
Biological functions
Signal transduction (via binding secretory phospholipase A2 isoforms)Endocytosis (clearance of extracellular sPLA2)Regulation of cell proliferation (via MAPK cascade in select cell types)Cellular senescence and apoptosis (tumor-suppressive function)Immune response (primarily as autoantigen in podocytes)Regulation of bone marrow mast cell function, neutrophil adhesion, and elastase release
04
Disease associations
Membranous nephropathy (primary/idiopathic form; causal antigen)Glomerulonephritis (membranoproliferative type)Cancer (acts as mediator of tumor-suppressive responses)Potential inflammation and tissue injury in other contexts (such as asthma)
05
Safety considerations
Risk of immunosuppression (increased infection and cancer risk related to drug therapy for PLA2R1-associated nephropathy)Difficulty in predicting disease outcome based on single anti-PLA2R1 antibody measurementsLack of full understanding of mechanism in cancer and inflammation
06
Interacting drugs
Rituximab (immunosuppressive biologic, used in anti-PLA2R1 antibody-positive membranous nephropathy)
1 more in the full profile.
07
Biomarkers
Anti-PLA2R1 antibodies (circulating autoantibody level correlates with diagnosis and disease severity)Proteinuria, creatinine, serum albumin (for disease monitoring in nephropathy)PLA2R1 gene risk alleles (associated with susceptibility to membranous nephropathy)
Beyond the preview
Go deeper on Phospholipase A2 receptor 1 (PLA2R1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phospholipase A2 receptor 1 (PLA2R1).